BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33660404)

  • 1. Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010-2019.
    Liu X; Wu S; Sun J; Ni S; Lu L; Hu W; Wei H; Zou Y; Li T; Li J; Mijiti B; Fang P; Zhao L; Zhou H; Xing X; Niu H; Cao Y
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00729. PubMed ID: 33660404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
    Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
    Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trend of drug clinical trials in mainland China from 2009 to 2020.
    Cao Y; Liao L; Liu X; Zheng Q; Xu Z; Niu H
    Curr Med Res Opin; 2022 Sep; 38(9):1499-1507. PubMed ID: 35855662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021.
    Bo C; Wang T; Hou C; Han J; Chen L; Zhang H; Wang L; Li H
    CNS Neurosci Ther; 2022 Aug; 28(8):1229-1239. PubMed ID: 35642775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Clinical Trials in Mainland China Over the Past Decade (From 2009 to 2020).
    Wu WW; Ji X; Wang H; Chen F; Ding Q; Zhang GD; Li M; Wang SS; Ni MM; Liu QQ; Xu J; Wang Q
    Front Med (Lausanne); 2021; 8():745676. PubMed ID: 34671625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Pharmacological Activity of
    Sánchez M; González-Burgos E; Iglesias I; Lozano R; Gómez-Serranillos MP
    Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32294991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research and development of mAb drugs in China: a look from policy perspectives.
    Jiang R; Sun Y; Ung C; Dong X; Kong X; Hu Y; Shao R
    Hum Vaccin Immunother; 2019; 15(11):2695-2705. PubMed ID: 31116629
    [No Abstract]   [Full Text] [Related]  

  • 8. The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic review.
    Chen H; Zhou Y; Han X; Shi Y
    Lancet Reg Health West Pac; 2021 Mar; 8():100097. PubMed ID: 34327425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in innovative pediatric drug development in China based on clinical trial registration data.
    Wu WW; Ji X; Mou XS; Ma XY; Huang YT; Zhang JY; Zhang JX; Xie XR; Mao NY; Xu J
    Front Med (Lausanne); 2023; 10():1187547. PubMed ID: 37484857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinued drugs in 2008: endocrine and metabolic.
    Colca JR
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1243-55. PubMed ID: 19678796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020.
    Wu X; Zhang F; Yu M; Wang H
    Clin Pharmacol Drug Dev; 2022 Aug; 11(8):903-909. PubMed ID: 35711154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.
    Zhong Q; Tao Y; Chen H; Zhou Y; Huang L; Han X; Shi Y
    Lancet Reg Health West Pac; 2021 Jun; 11():100151. PubMed ID: 34327360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020.
    Chen K; Jiang K; Tang L; Chen X; Hu J; Sun F
    Front Oncol; 2021; 11():647110. PubMed ID: 34084744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent landscape and trends for industry-sponsored pediatric clinical trials in China from 2013 to 2022.
    Liu C; Liu Y; Ou L; Qi Y; Zhang J
    Pediatr Investig; 2024 Mar; 8(1):12-20. PubMed ID: 38516137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress on clinical trials of cancer drugs in China, 2019].
    Huang HY; Wu DW; Wang HX; Wang J; Fan Q; Wang SH; Bai Y; Yu Y; Fang Y; Sun C; Fang H; Bai H; Wang X; Liu ZY; Jiang M; Liu Z; Wang XH; Li HY; Li N; Cao C; Xu BH; Sun Y; He J
    Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):127-132. PubMed ID: 32135647
    [No Abstract]   [Full Text] [Related]  

  • 16. Trends of Clinical Trials for Drug Development in Rare Diseases.
    Sakate R; Fukagawa A; Takagaki Y; Okura H; Matsuyama A
    Curr Clin Pharmacol; 2018; 13(3):199-208. PubMed ID: 29866013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current clinical trials on breast cancer in China: A systematic literature review.
    Fan Y; Xu B
    Cancer; 2020 Aug; 126 Suppl 16():3811-3818. PubMed ID: 32710659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress on clinical trials of common gastrointestinal cancer drugs in China from 2012 to 2021].
    Huang HY; Wu DW; Zhu Q; Yu Y; Wang HX; Wang J; Ga M; Meng XY; Du JT; Miao SM; Zhao ZX; Wang X; Shang P; Guo MJ; Liu LH; Tang Y; Li N; Cao C; Xu BH; Sun Y; He J
    Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):276-281. PubMed ID: 35316878
    [No Abstract]   [Full Text] [Related]  

  • 20. Discontinued drugs in 2012: endocrine and metabolic.
    Colca JR
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1305-13. PubMed ID: 23961717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.